To the Editor In 2010, Amminger et al1 showed a 29% reduction in transition to full-blown psychosis in ultrahigh risk patients who had received an ω-3 fatty acid supplement for 12 weeks, compared with placebo, when evaluated after 1 year. In JAMA Psychiatry, McGorry et al2 published a study that failed to show a benefit of ω-3 supplementation compared with placebo in transition to psychosis rates.
Lin D. Negative Psychosis Prevention Trials. JAMA Psychiatry. 2017;74(6):651–652. doi:10.1001/jamapsychiatry.2017.0187
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: